Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

@article{So2010CanakinumabFT,
  title={Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.},
  author={Alexander So and Marc De Meulemeester and Andrey Pikhlak and Ahmet Eftal Y{\"u}cel and Dominik Richard and Valda Murphy and Udayasankar Arulmani and Peter Sallstig and Naomi Schlesinger},
  journal={Arthritis and rheumatism},
  year={2010},
  volume={62 10},
  pages={
          3064-76
        }
}
OBJECTIVE To assess the efficacy and tolerability of canakinumab, a fully human anti-interleukin-1β monoclonal antibody, for the treatment of acute gouty arthritis. METHODS In this 8-week, single-blind, double-dummy, dose-ranging study, patients with acute gouty arthritis whose disease was refractory to or who had contraindications to nonsteroidal antiinflammatory drugs and/or colchicine were randomized to receive a single subcutaneous dose of canakinumab (10, 25, 50, 90, or 150 mg; n = 143… 
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
TLDR
Canakinumab provided significant pain and inflammation relief and reduced the risk of new flares in these patients with acute gouty arthritis.
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study
TLDR
Improvements in HRQoL were seen in both treatment groups with a faster onset with canakinumab 150 mg compared with triamcinolone acetonide 40 mg, and improvements in physical health were observed at seven days post-dose in all treatment groups.
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
TLDR
Single canakinumab doses ≥50 mg or four 4-weekly doses provided superior prophylaxis against flares compared with daily colchicine 0.5 mg at 16 weeks.
Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence.
  • T. Bardin
  • Medicine
    Joint, bone, spine : revue du rhumatisme
  • 2015
Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.
TLDR
Efficacy of anakinra was shown to be non-inferior to treatment as usual for the treatment of acute gout flares, suggesting that anakinRA is an effective treatment alternative for acute g out flares.
Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares
TLDR
On-demand treatment with subcutaneous canakinumab 150 mg significantly relieved the pain and inflammation of a new gout flare, and reduced the risk of new flares in patients with acute gouty arthritis flares in whom standard treatment with non-steroidal anti-inflammatories and/or colchicine was inappropriate.
Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator
TLDR
Although generally well-tolerated, rilonACEpt in combination with indomethacin and rilonacept alone did not provide additional pain relief over 72 hours relative to indometHacin alone in patients with acute gout flare.
A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout
TLDR
Canakinumab appeared to be a viable, safe, and effective alternative to conventional therapies in this patient with gout who had limited therapeutic options, and a gradual, rapid, and significant reduction in pain.
Oral Huzhang granules for the treatment of acute gouty arthritis: protocol for a double-blind, randomized, controlled trial
TLDR
The aim of this trial is to clarify the treatment efficacy, safety, and recurrence control efficacy of Huzhang granules (HZG) in patients with GA showing dampness-heat syndrome and to provide evidence regarding the clinical efficacy and safety of Chinese medicine treatment for acute gouty arthritis.
Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases
TLDR
Anakinra may be efficient in gouty arthritis, is relatively well tolerated with short-term use, and could be a relevant option in managing g outy arthritis when conventional therapies are ineffective or contraindicated.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study
TLDR
It is demonstrated that rilonacept is generally well tolerated and may offer therapeutic benefit in reducing pain in patients with chronic refractory gouty arthritis, supporting the need for larger, randomised, controlled studies of IL1 antagonism such as with rilonACEpt for this clinical indication.
Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis.
TLDR
In a direct comparison of the 2 at the doses used, triamcinolone acetonide resulted in fewer rebound attacks and treatment failures than ACTH and required fewer reinjections.
Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis.
TLDR
Triamcinolone acetonide is as safe and effective as indomethacin in the treatment of acute gout, and is particularly useful in patients with contraindications to therapy with nonsteroidal antiinflammatory drugs.
Use of canakinumab in the cryopyrin-associated periodic syndrome.
TLDR
Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS and evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA).
Management of Acute and Chronic Gouty Arthritis
TLDR
The use of recombinant urate oxidase in patients with chronic gout is limited by the need for parenteral administration, the potential antigenicity and production of anti-urate oxidase antibodies, and declining efficacy.
Overview of the Management of Acute Gout and the Role of Adrenocorticotropic Hormone
TLDR
Treatment of acute gout is discussed, emphasizing the use of corticotrophin (adrenocorticotropic hormone; ACTH) and the evidence on which it is based, and the most important determinant of therapeutic success is not which NSAID is chosen, but rather how soon NSAID therapy is initiated.
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.
TLDR
Treatment with weekly rilonacept provided marked and lasting improvement in the clinical signs and symptoms of CAPS, and normalized the levels of SAA from those associated with risk of developing amyloidosis.
Systemic corticosteroids for acute gout (Review)
TLDR
There is inconclusive evidence for the efficacy and effectiveness of systemic corticosteroids in the treatment of acute gout, but patients with gout did not report serious adverse effects from systemic cortICosteroids, when used short term.
Systemic corticosteroids for acute gout.
TLDR
There is inconclusive evidence for the efficacy and effectiveness of systemic corticosteroids in the treatment of acute gout, but patients with gout did not report serious adverse effects from systemic cortICosteroids, when used short term.
...
...